Palifermin, a recombinant human keratinocyte growth factor, was FDA-approved in 2004 to reduce the incidence and duration of oral mucositis in patients receiving intensive chemotherapy and radiotherapy for hematologic cancers [34]. Here, FGF7 is linked to hematopoietic and lymphoid cell neoplasm.